PMID- 31125000
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20200224
IS  - 2531-6745 (Electronic)
IS  - 0392-4203 (Print)
IS  - 0392-4203 (Linking)
VI  - 90
IP  - 2
DP  - 2019 May 23
TI  - Adverse events during testosterone replacement therapy in 95 young hypogonadal 
      thalassemic men.
PG  - 228-232
LID - 10.23750/abm.v90i2.8477 [doi]
AB  - BACKGROUND: Hormonal treatment of hypogonadism in thalassaemia major (TM) is a 
      complex issue due to the co-existence of other contributing factors such as 
      severity of iron overload, associated chronic liver disease and other endocrine 
      complications. OBJECTIVES: Data about adverse events (AEs) of testosterone 
      replacement therapy (TRT) in hypogonadal males with TM is scarce.We report the 
      adverse events registered during TRT in 95 young patients with TM. RESULTS: These 
      AEs included gynecomastia, documented in 41/95 (43.1%) TM patients of mild to 
      moderate severity (90%). Persistent pain in the injection site and local 
      reactions to testosterone (T) skin patch occurred in a third of patients. 
      Priapism was reported in 2 patients on treatment with intramuscular T enanthate. 
      In both patients, substitution with T gel was successful, and no recurrence 
      during the following 24 months was observed. CONCLUSIONS: Clinicians should 
      exercise caution when considering TRT for hypogonadal men with TM. 
      (www.actabiomedica.it).
FAU - De Sanctis, Vincenzo
AU  - De Sanctis V
AD  - Quisisana Hospital, Ferrara. vdesanctis@libero.it.
FAU - Soliman, Ashraf T
AU  - Soliman AT
FAU - Daar, Shahina
AU  - Daar S
FAU - Di Maio, Salvatore
AU  - Di Maio S
LA  - eng
PT  - Journal Article
DEP - 20190523
PL  - Italy
TA  - Acta Biomed
JT  - Acta bio-medica : Atenei Parmensis
JID - 101295064
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Adolescent
MH  - Cohort Studies
MH  - Comorbidity
MH  - Drug-Related Side Effects and Adverse 
      Reactions/epidemiology/*etiology/physiopathology
MH  - Hormone Replacement Therapy/*adverse effects/methods
MH  - Humans
MH  - Hypogonadism/diagnosis/*drug therapy/*epidemiology
MH  - Male
MH  - Monitoring, Physiologic/methods
MH  - Patient Safety
MH  - Prevalence
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Testosterone/administration & dosage/*adverse effects
MH  - Treatment Outcome
MH  - Young Adult
MH  - beta-Thalassemia/diagnosis/*epidemiology
PMC - PMC6776204
COIS- Each author declares that he or she has no commercial associations (e.g. 
      consultancies, stock ownership, equity interest, patent/licensing arrangement 
      etc.) that might pose a conflict of interest in connection with the submitted 
      article
EDAT- 2019/05/28 06:00
MHDA- 2020/02/25 06:00
PMCR- 2019/01/01
CRDT- 2019/05/25 06:00
PHST- 2019/05/14 00:00 [received]
PHST- 2019/05/14 00:00 [accepted]
PHST- 2019/05/25 06:00 [entrez]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - ACTA-90-228 [pii]
AID - 10.23750/abm.v90i2.8477 [doi]
PST - epublish
SO  - Acta Biomed. 2019 May 23;90(2):228-232. doi: 10.23750/abm.v90i2.8477.